A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

Study Identifier
M06-837
CT.gov Identifier
NCT00445432
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Crohn's Disease (CD)
    • Study Drug
  • adalimumab
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    15 - 75 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Subjects who successfully enrolled in and completed the M04-729, (NCT00445939) study
    Exclusion Criteria:
    - Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study

    Protocol Summary

    To demonstrate the efficacy and safety of adalimumab for the maintenance of clinical

    remission in Japanese subjects with Crohn's disease.

    Study Locations

    Location
    Status
    Location
    Site Ref # / Investigator 46965
    Aichi, Japan
    Status
    Not applicable
    Location
    Site Ref # / Investigator 46977
    Aichi, Japan
    Status
    Not applicable
    Location
    Site Ref # / Investigator 46978
    Aichi, Japan
    Status
    Not applicable
    Location
    Site Ref # / Investigator 46979
    Aichi, Japan
    Status
    Not applicable
    Location
    Site Ref # / Investigator 46922
    Chiba, Japan
    Status
    Not applicable
    Location
    Site Ref # / Investigator 46974
    Chiba, Japan
    Status
    Not applicable
    Showing {first} - {last} of {total} Results